The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery
Status:
NOT_YET_RECRUITING
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. "Investigational" means that the has not yet been approved by the U.S. Food \& Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glucagon.
Phase:
PHASE1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)